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 1  INTRODUCTION 
 
Dry Powder Inhalers (DPIs) are the result of the development of two technologies: powder 
technology and device technology. Particle deposition in the respiratory tract is affected by 
many aerosol particle properties such as particle size, shape, density, charge, and 
hygroscopicity.1 In particular, particle size is of great importance as it is known that particle-
particle interactions within DPI formulations are related to van der Waals forces. Therefore, 
particle size is the most important physical property and design variable of a DPI formulation. 
Several studies were reported on the effect of drug particle size on DPI performance, showing 
that the preferred drug particle size is between 1-5 µm.2 However, in literature, the effect of 
carrier particle size distribution (PSD) on drug aerosolisation efficiency has received less 
attention and reported in dissimilar manner.3 Nevertheless, it should be noted that there is rare 
studies aimed to show the effect of carrier particle size as a single variable factor on DPI 
performance. In this study, the effect of lactose particle size distribution on budesonide 
adhesion, content uniformity and in vitro aerosolisation performance was investigated. 
 
 
2 METHODS AND RESULTS 
 
2.1  Micromeretic, solid state, and flow properties 
 
Commercial α-lactose monohydrate powder was sieved to obtain different lactose samples 
with different size fractions as follows: A (90-125 µm), B (63-90 µm), C (63-45 µm), D (20-
45 µm) and E (< 20 µm). Laser diffraction and scanning electron microscope observations 
showed that different lactose powders have considerably different size distributions and 
different surface topographies (Figure 1). Span values indicated narrower size distributions for 
lactose powders with smaller volume mean diameter (VMD) (r2=0.9792, Span= 0.417 ln 
(VMD) +2.6386). Fine particle lactose (FPL<10µm), which was reported to have dominating 
effect on DPI performance,4 was absent in sample A, B, and C whereas sample D and E 
Particulate materials: Synthesis, Characterisation, Processing, and Modelling. The Royal 
Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge CB4 
0WF, UK. 
contain 5.2±0.2% and 36.8±2.4% of FPL<10µm, respectively. Higher specific surface area 
(SSAv) was obtained for lactose samples with smaller volume mean diameter, higher span 
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Figure 2  Roughness, surface factor, and shape factor (a); angularity and roundness (b) for 
different lactose samples. 
 Particle shape image analysis showed that lactose powders with smaller size have higher 
shape factor, higher surface factor, smaller roughness (Figure 2a), higher roundness, and 
higher angularity (Figure 2b). This indicates smoother surface and higher degree of shape 
regularity for lactose particles with smaller size. 
 Differential scanning calorimeter was employed to characterise the crystalline nature of 
all lactose samples (Figure 2). All lactose samples showed the typical thermal curve of α-
lactose monohydrate consisting of two distinctive endothermic peaks at about 148° C and 
219°C and one smaller exothermic peak at about 175 °C corresponding to dehydration of 
crystalline hydrate water, melting of α-lactose, and crystallisation of amorphous lactose. 5  
 Lactose samples with smaller size showed larger exothermic peak at about 175 °C, which 
is indicative of higher amorphous content. By calculating % amorphous content of different 
lactose samples,6 linear relationship was established showing that the lactose samples with 




Figure 3  Differential scanning calorimetery thermograms of different lactose samples. 
 
 True density (Dtrue) measurements provided by helium pycnometery showed that lactose 
powders with higher volume mean diameter have smaller true density (linear, r2=0.9932). On 
the other hand, lactose powders with higher volume mean diameter showed higher bulk 
density (Db) (linear, r2=0.8943) and higher tap density (Dt) (linear, r2=0.8244). Lactose 
powders with smaller VMD showed higher Carr’s index values (linear, r2=0.9177) (indicating 
poorer flow properties) and higher porosity (linear, r2=0.914).  
 
2.2  Uniformity, adhesion, and in vitro aerosolisation performance assessments 
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Five different formulations were prepared by blending micronized budesonide (median 
diameter=3.2±0.2 µm) with different lactose samples (A, B, C, D, and E) in a ratio of 1:67.5 
w/w in TurbulaTM mixer for 30 min. From each blend, at least seven samples were collected 
randomly for quantification of budesonide content using High Performance Liquid 
Chromatography. All blends showed similar drug content potency (p<0.05); however lactose 
particles with smaller VMD produced higher coefficient of variation (CV%) of budesonide 
indicating reduced drug content homogeneity (Figure 4a). This can be attributed to poorer 
flowability and wider size distribution for lactose powders with smaller particle size as shown 
previously. In fact, direct linear relationships were obtained when plotting coefficient of 




Figure 4  Relationship between lactose VMD and budesonide CV (a), amount remained on 
top of 20 µm sieve (b), FPF (c), DS (d), IL (e), and amount deposited on IP (f).  
 
 Air jet sieving was employed to evaluate drug-carrier adhesion properties for all 
formulations. Less amounts of drug remained on top of the 20 µm sieve was obtained for the 
lactose particles with smaller VMD (Figure 4b) indicating weaker drug-carrier adhesion. This 
could be, in part, attributed to higher collision and friction forces during mixing process for 
lactose powders with higher VMD, which act as adhesive forces. 
 In vitro aerosolisation performance of different formulations was analysed using Multi 
Stage Liquid Impinger (MSLI) attached to Aerolizer® inhaler device. The results showed that 
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despite using the same batch of budesonide in all formulations; budesonide aerodynamic 
particle size was dependent on lactose particle size. Lactose particles with smaller size 
produced budesonide particles with smaller aerodynamic size upon inhalation. Higher fine 
particle fraction (FPF) (Figure 4c), higher dispersibility (Figure 4d), and smaller impaction 
loss (IL) (Figure 5e) of budesonide were obtained for lactose particles with smaller volume 
mean diameter indicating improved aerosolisation performance. This could be attributed to 
smaller drug-carrier adhesion for lactose powders with smaller volume mean diameter (Figure 
4b) and consequently improved drug-carrier detachment efficiency upon inhalation. However, 
it was noticed that the smaller the lactose volume mean diameter, the higher the amounts of 
budesonide deposited on throat (IP) (Figure 4f), which is disadvantageous in terms of 




Figure 5 FPF of budesonide in relation to lactose shape factor, surface factor, roughness, 
roundness, compactness, porosity, SSAv, FPL< 5µm, eR, Db, and Dt. 
 
 Direct linear relationship (r2=0.9822) was established between amounts of drug deposited 
on throat and fine particle lactose (FPL<10µm) (figure not shown). Lactose powders with poorer 
flowability produced higher amounts of budesonide remained in inhaler device and deposited 
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on throat. It was assumed that high powder cohesiveness for lactose D and E (as indicated by 
higher Carr’s index values) could not be totally overcome during inhalation process, leading to 
the formation of aggregates remained in the inhaler device and/or deposited on throat. The 
smaller the volume mean diameter of lactose, the smaller the amounts of budesonide deposited 
on MSLI stage 1 and the higher the amounts of drug deposited on MSLI stages 2, 3, 4, and 
filter.Figure 5 shows that higher fine particle fraction of budesonide was obtained when 
lactose powders with smaller roughness, higher shape factor, higher surface factor, higher 
roundness, higher compactness, higher porosity, higher specific surface area, higher fine 
particle lactose, higher simplified shape factor, smaller bulk density, and smaller tap density
 
were used. This indicates that the aerosolisation performance is better when carrier particles 
with smoother surface, regular shape, higher surface area, higher content of fines and smaller 





This study showed that the smaller the carrier size the better the drug aerosolisation efficiency. 
However, the use of carrier powders with smaller particle size is disadvantageous in terms of 
reduced dose homogeneity, higher potential of side effects possibility, and reduced 





CI:    Carr’s index;         CV:   coefficient of variation;     
Db:    bulk density;        DPI:   dry powder inhaler;  
DS:   dispersibility;        Dt:   tap density; 
Dtrue:   true density;               
eR:    simplified shape factor;    
FPF:   fine particle fraction;     FPL:   fine particle lactose; 
IL:    impaction loss;       IP:   induction port;       
MMAD:  mass median aerodynamic diameter  MSLI:  Multi Stage Liquid Impinger; 
PSD:   particle size distribution;     SEM:   scanning electron microscope; 
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